Ginkgetin inhibits Oral Squamous Cell Carcinoma (OSCC)malignant progression by regulating ferroptosis mediated via p53/SLC7A11/GPX4 pathway

Read full text Summarise with VIRAT
Authors: Yi Shi, Weizhong Wu, Xiaohong Jin
Cited by: 0
References: 48

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Ginkgetin can participate in the regulation of ferroptosis and play an anti-cancer role. The solute carrier family 7 member 11 (SLC7A11) knockdown plasmid was transfected into oral squamous cell carcinoma (OSCC) cells (Cal27 and SCC9), and then treated with p53 inhibitors PFT-α, Ginkgetin, ferroptosis activator Erastin and inhibitor FER-1, respectively. Ginkgetin could inhibit the malignant biological behavior of OSCC cells, promote ferroptosis, promote p53 level, and reduce SLC7A11 and GPX4 levels. After the application of FER-1, OSCC cell multiplication, movement and invasion were notably elevated. After the application of PFT-α, the ferroptosis of OSCC was inhibited, and the level of SLC7A11 was decreased. On this basis, SLC7A11 was silenced, showing that the inhibition level of ferroptosis wasweakened, p53 was significantly raised, SLC7A11 and GPX4 were obviously lessened. Ginkgetin can promote ferroptosis of OSCC by activating p53 and inhibiting SLC7A11/GPX4 signaling, thereby exerting anti-cancer effects.

Fields of Study & Subjects

Ferroptosis and cancer prognosis Cancer-related Molecular Pathways Head and Neck Cancer Studies

Publication details

Journal / source
Boletin Latinoamericano y del Caribe de plantas Medicinales y Aromaticas
Volume
25
Issue
2
Pages
239–281
Publication date
21 March 2026
Language
EN